S3 Ep50: FDA Approval Insights: Selinexor in Relapsed/Refractory DLBCL
S3 Ep49: FDA Approval Insights: Daratumumab/Carfilzomib/Dexamethasone in Myeloma
S3 Ep48: Gandara Evaluates Opportunities for Virtual Education, Expansion, and Engagement Amid COVID-19
S3 Ep47: Garcia-Manero Previews Potential New Therapeutic Standards in TP53-Mutated MDS/AML
S3 Ep46: Gutierrez Provides Insight on Bridging Gaps in Cancer Care Among Hispanic Patients
S3 Ep45: Subbiah Tempers Concerns Regarding Pembrolizumab Approval in TMB-High Solid Tumors
S3 Ep44: O’Regan on Protocols, Best Practices, and Virtual Etiquette for Cancer Care in Light of COVID-19
S3 Ep43: FDA Approval Insights: Tazemetostat in Relapsed/Refractory Follicular Lymphoma
S3 Ep42: FDA Approval Insights: Fixed-Dose Pertuzumab/Trastuzumab in HER2+ Breast Cancer
S3 Ep41: FDA Approval Insights: Lurbinectedin in Metastatic SCLC
S3 Ep40: Tripathy Spotlights the State of Treatment in Metastatic HER2+ Breast Cancer
S3 Ep39: FDA Approval Insights: Atezolizumab Plus Cobimetinib and Vemurafenib in BRAF V600+ Advanced Melanoma
S3 Ep38: Giri and Gomella on Fostering a New Framework for Genetic Testing Guidelines in Prostate Cancer
S3 Ep37: Tolaney Talks Tailored Treatment Strategies in HER2+ Breast Cancer
S3 Ep36: Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer
S3 Ep35: Coleman and Slomovitz Continue the Discussion on Maintenance PARP Inhibition in Ovarian Cancer
S3 Ep34: GU Experts Review Treatment Options, Remaining Challenges, and Future Research in Penile Cancer
S3 Ep33: FDA Approval Insights: Avelumab in Metastatic Urothelial Carcinoma
S3 Ep32: Talking Tumors: Evaluating Early-Stage Breast Cancer Cases in the COVID-19 Era
S3 Ep31: Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy
S3 Ep30: Pegram Unpacks Pivotal Data in Breast Cancer
S3 Ep29: Research Reflections: Braunstein Breaks Down Top ASCO 2020 Abstracts in Myeloma
S3 Ep28: Markman and Monk Provide Perspective on the Utility of PARP Inhibitors in Ovarian Cancer
S3 Ep27: Dizon Discusses Elements of Sexual Health in Gynecologic Cancer
S3 Ep26: FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory MCL
S3 Ep25: DiNardo Discusses VIALE-A and Venetoclax Combo in AML
S3 Ep24: Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess
S3 Ep23: Examining ADAURA and the Advantages of Adjuvant Osimertinib in EGFR+ NSCLC
S3 Ep22: FDA Approval Insights: Selpercatinib in RET+ NSCLC and Thyroid Cancers
S3 Ep21: Research Reflections: Sarcoma Experts Consider Emerging Evidence for Novel Combos
S3 Ep20: First of its Kind MMRF CureCloud Makes Way for Precision Medicine in Myeloma
S3 Ep19: Marvels in Medicine: Dr. Jordan on Undertaking an Unforeseen Career in Breast Cancer
S3 Ep18: FDA Approval Insights: Ramucirumab/Erlotinib in EGFR+ Metastatic NSCLC
S3 Ep17: Talking KRAS-Targeted Therapy in NSCLC With Dr. Drilon
S3 Ep16: Research Reflections: Weinberg Weighs in on Thought-Provoking Data in CRC
S3 Ep15: FDA Approval Insights: Olaparib in HRR-Mutant mCRPC
S3 Ep14: Marvels in Medicine: Vokes’s Venture to Bring Combined Modality Care to Patients With Cancer
S3 Ep13: Integrating Nutrition Into the Continuum of Cancer Care
S3 Ep12: FDA Approval Insights: Nivolumab/Ipilimumab in Advanced NSCLC
S3 Ep11: Marvels in Medicine: Dr. Gradishar on the Personal Pursuit of Precision Medicine in Breast Cancer
S3 Ep10: Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma
S3 Ep9: Reviewing the Risk-Benefit Ratio of Adjuvant and Neoadjuvant Approaches in Melanoma
S3 Ep8: Chowdhary Covers Risk-Reducing Strategies and Recommendations During the COVID-19 Era
S3 Ep7: Marvels in Medicine: Dr. Karlan on Breaking Down Gender Barriers in Gynecologic Oncology
S3 Ep6: Dr. Burris and Dr. Graff Talk COVID-19 and Cancer Care, Telemedicine, and ASCO Initiatives
S3 Ep5: FDA Approval Insights: Subcutaneous Daratumumab in Multiple Myeloma
S3 Ep4: McGregor Details GU Treatment Guidelines During COVID-19 Pandemic
S3 Ep3: FDA Approval Insights: Olaparib/Bevacizumab in Advanced Ovarian Cancer
S3 Ep2: Talking Tumors: Exploring Management Strategies in Multiple Myeloma
S3 Ep1: Making Headway in GI Malignancies in Miami
next page